MD Anderson Events
CANCELLED-Pediatrics Research Seminar Series: Regulation of the Assembly and Function of Cullin-RING Ubiquitin Ligases
The Department of Pediatrics Research invites investigators with expertise in the field of pediatric tumors or relevant areas of research to present the recent findings to faculty, students and post-doctoral fellows.
Date: 1/8/13, 9am to 10am
Time: 1/8/13, 9am to 10am
Location: Smith Research Building, Conference SRB1.122
Facilitator: Vidya Gopalakrishnan, PhD
Speaker: Raymond Deshaies, PhD
Speaker Bio: Raymond Deshaies, PhD is a Professor and Investigator at California Institute of Technology. Cullin-RING ubiquitin ligases (CRLs) comprise a large family of ~250 enzymes. SCF and other CRL enzymes play key roles i the regulatory biology of normal and diseased cells. Some CRLs have been implicated as tumor suppressors whereas others have a proto-oncogenic function. Given the large number of different CRL complexes that can be assembled in cells, a key question is how the repertoire of CRL enzymes is regulated to yield the appropriate balance of growth-promoting (eg SCF-Skp2) and growth-restraining (eg SCF-Cdc4) activities. In my seminar, I will discuss recent advances that have been enabled us to develop a specific and general model that explains how the cellular repertoire of CRL complexes is determined.
Contact: Hector Jimenez - (713) 563-5394 - email@example.com
- Thoracic, Head and Neck Cancer Research Seminar
- Department of Radiation Oncology Special Seminar
- Department of Molecular & Cellular Oncology Seminar
- Pancreas Cancer Seminar Series
- S2M Science to Medicine Seminar "Regulation of Enhancer Overactivation by a Protein Complex Containing RACK7/ZMYND8 and KDM5C"
- Annual Postdoctoral Science Symposium
- Department of Translational Molecular Pathology Distinguished Speaker Seminar Series
- Dr. Mina Bissell: Why don’t we get more cancer: The critical role of Extracellular Matrix and Microenvironment in metastasis and dormancy
- Updates in Palliative Care and Physician Board Review Course
- New Immune Checkpoints, New Cancer Immunotherapies